Cardiologists make history, treat world’s first patient with new interventional device for chest pain

Michael Walter | February 27, 2024 | Cardiovascular Business | Interventional Cardiology

Image of the A-FLUX Reducer System for chest pain by VahatiCor

VahatiCor, a new medical device company associated with California-based T45 Labs, announced that the very first patient has been successfully treated with its A-Flux Reducer System for chest pain.

The A-Flux Reducer System is intended to be a new therapy option for “no-option” chest pain patients who see no benefits from other available interventional or surgical treatments. Interventional cardiologists implant the self-expandable device percutaneously into the patient’s coronary, where it increases blood flow in a way that provides more oxygen to the heart and relieves symptoms. It was designed to “conform seamlessly” to any patient’s anatomy, according to VahatiCor, and it can be repositioned or retrieved as necessary.

The first successful implant of this new device was performed on an angina patient from Canada by interventional cardiologists Jean-Michel Paradis, MD, and Can Manh Nguyen, MD, at the Quebec Heart and Lung Institute.

VahatiCor's A-Flux Reducer System. The A-Flux Reducer System is intended to be a new therapy option for “no-option” chest pain patients who see no benefits from other available interventional or surgical treatments. Interventional cardiologists implant the self-expandable device percutaneously into the patient’s coronary, where it increases blood flow in a way that provides more oxygen to the heart and relieves symptoms. It was designed to “conform seamlessly” to any patient’s anatomy.

VahatiCor's A-Flux Reducer System is intended to be a new therapy option for “no-option” chest pain patients who see no benefits from other available interventional or surgical treatments.

“We have many interventional or surgical revascularization options for patients with advanced large coronary artery disease,” Paradis said in a statement.. “However, a significant proportion still suffer from angina. The A-Flux Reducer could help to fill that therapeutic void. It was an honor to perform the first-in- human implant and the patient is doing great.”

“The A-Flux Reducer System is a promising intervention with the potential to provide a predictable and low-risk treatment for a growing population of patients with angina symptoms that do not respond well to medicines and lifestyle changes,” Nguyen added.

In the same statement, Howard Edelman, CEO of VahatiCor, highlighted the new device’s potential to treat microvascular angina.

“We are encouraged by the positive early clinical experience with A-Flux and are moving forward quickly to a larger study that will support the availability of the device for more patients,” he said.

CT-first strategy the most effective path forward when evaluating stable chest pain

Cardiologists make history, perform TTVR with new-look valve for first time in U.S.

Cardiologists make history, becoming first to use FDA-cleared retrieval device to remove a heart tumor

‘A watershed moment’: HeartFlow praises new chest pain guidelines

ACC, AHA release long-awaited chest pain guidelines

CCTA an effective initial imaging option for patients with stable chest pain

Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

Health Exec

Major association of physicians presents itself as a go-to alternative vs. the government on vaccine expertise

One of the most formidable societies of medical professionals in the U.S. is going toe-to-toe with Robert F. Kennedy’s HHS over changing vaccination recommendations.

Health Exec

Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging

Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.